Comparative Pharmacology
Head-to-head clinical analysis: OXACILLIN SODIUM versus VERSAPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXACILLIN SODIUM versus VERSAPEN.
OXACILLIN SODIUM vs VERSAPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxacillin is a penicillinase-resistant beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking the transpeptidation step in peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamase.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
1-2 grams IV every 4-6 hours.
500 mg IV every 6 hours or 1 g IV every 8 hours for moderate infections; 2 g IV every 4 hours for severe infections.
None Documented
None Documented
0.3-0.8 hours in adults with normal renal function; prolonged to 1-2 hours in neonates and 2-5 hours in patients with severe renal impairment (CrCl <10 mL/min)
0.5-1.0 hour (normal renal function); prolonged to 10-20 hours in anuria. Requires dose adjustment in renal impairment.
Renal (70-80% unchanged by tubular secretion and glomerular filtration); biliary (minor, approximately 10%)
Renal: 60-70% unchanged via glomerular filtration and tubular secretion. Biliary: <10% excreted unchanged. Fecal: 20-30% as metabolites.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic